PURPOSE: To test whether transglutaminase 2 (TGase 2) inhibitor GK921 alone reverses renal cell carcinoma (RCC) tumor growth. RCC is resistant to both radiation and chemotherapy, and the prognosis remains poor. Despite the recent therapeutic success of vascular endothelial growth factor inhibition in RCC, approximately one-third of RCC patients develop metastatic disease. The expression of TGase 2 is markedly increased in most RCC cell lines, as well as in clinical samples. METHODS: Previously, we introduced the quinoxaline derivative GK13 as a lead compound for TGase 2 inhibitor. The inhibitory effect of GK13 on TGase 2 was improved in GK921 (3-(phenylethynyl)-2-(2-(pyridin-2-yl)ethoxy)pyrido[3,2-b]pyrazine). GK921 efficacy was tested using sulforhodamine in vitro as well as a xenograft tumor models using ACHN and CAKI-1 RCC cells. RESULTS: GK921 showed cytotoxicity to RCC (average GI50 in eight RCC cell lines: 0.905 μM). A single treatment with GK921 almost completely reduced tumor growth by stabilizing p53 in the ACHN and CAKI-1 preclinical xenograft tumor models. CONCLUSION: TGase 2 inhibitor GK921 abrogates RCC growth in xenograft tumor models, suggesting the possibility of a new therapeutic approach to RCC.
PURPOSE: To test whether transglutaminase 2 (TGase 2) inhibitor GK921 alone reverses renal cell carcinoma (RCC) tumor growth. RCC is resistant to both radiation and chemotherapy, and the prognosis remains poor. Despite the recent therapeutic success of vascular endothelial growth factor inhibition in RCC, approximately one-third of RCCpatients develop metastatic disease. The expression of TGase 2 is markedly increased in most RCC cell lines, as well as in clinical samples. METHODS: Previously, we introduced the quinoxaline derivative GK13 as a lead compound for TGase 2 inhibitor. The inhibitory effect of GK13 on TGase 2 was improved in GK921 (3-(phenylethynyl)-2-(2-(pyridin-2-yl)ethoxy)pyrido[3,2-b]pyrazine). GK921 efficacy was tested using sulforhodamine in vitro as well as a xenograft tumor models using ACHN and CAKI-1 RCC cells. RESULTS: GK921 showed cytotoxicity to RCC (average GI50 in eight RCC cell lines: 0.905 μM). A single treatment with GK921 almost completely reduced tumor growth by stabilizing p53 in the ACHN and CAKI-1 preclinical xenograft tumor models. CONCLUSION:TGase 2 inhibitor GK921 abrogates RCC growth in xenograft tumor models, suggesting the possibility of a new therapeutic approach to RCC.
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: John D Hainsworth; David M Waterhouse; William C Penley; Dianna L Shipley; Dana S Thompson; Charles D Webb; F Anthony Greco Journal: Cancer Invest Date: 2013-04-24 Impact factor: 2.176
Authors: Maria V Yusenko; Roland P Kuiper; Tamas Boethe; Börje Ljungberg; Ad Geurts van Kessel; Gyula Kovacs Journal: BMC Cancer Date: 2009-05-18 Impact factor: 4.430
Authors: B Min; H Park; S Lee; Y Li; J-M Choi; J Y Lee; J Kim; Y D Choi; Y-G Kwon; H-W Lee; S-C Bae; C-O Yun; K C Chung Journal: Oncogene Date: 2015-11-16 Impact factor: 9.867
Authors: H Yu; R Liu; B Ma; X Li; H-Y Yen; Y Zhou; V Krasnoperov; Z Xia; X Zhang; A M Bove; M Buscarini; D Parekh; I S Gill; Q Liao; M Tretiakova; D Quinn; J Zhao; P S Gill Journal: Br J Cancer Date: 2015-07-16 Impact factor: 7.640
Authors: Piotr Popławski; Jacek R Wiśniewski; Eddy Rijntjes; Keith Richards; Beata Rybicka; Josef Köhrle; Agnieszka Piekiełko-Witkowska Journal: PLoS One Date: 2017-12-22 Impact factor: 3.240
Authors: Sung Han Kim; Weon Seo Park; Eun Young Park; Boram Park; Jungnam Joo; Jae Young Joung; Ho Kyung Seo; Kang Hyun Lee; Jinsoo Chung Journal: PLoS One Date: 2017-06-27 Impact factor: 3.240